This company has shut down. Oncorus is no longer operating — its last tracked round was a Post-IPO Debt in 2022.
Explore the Startup GraveyardOncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
Oncorus has raised $20.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in April 2022.
Oncorus's investors include Perceptive Advisors, IMM Investment, Deerfield, MPM Capital, Cowen Healthcare Investments.
Oncorus is headquartered in Cambridge, United States.
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
Oncorus is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oncorus — Funding & Investors." VCBacked, April 5, 2022, https://www.vcbacked.co/company/oncorus. Accessed August 13, 2026.
VCBacked. (2022). Oncorus — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/oncorus
{{cite web |title=Oncorus — Funding & Investors |url=https://www.vcbacked.co/company/oncorus |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated